Sitagliptin (MK 0431) for type 2 diabetes - horizon scanning review
NHSC
Record ID 32005001258
English
Authors' objectives:
This study aims to assess the effectiveness of sitagliptin (MK 0431) for type 2 diabetes.
Authors' recommendations:
Sitagliptin (MK 0431) belongs to the new class of incretin enhancer drugs that also includes LAF237 (Vildagliptin) and exenatide. Sitagliptin is administered orally and is in clinical trials in addition to, and as a substitute for, current glucose-lowering therapies in patients with type 2 diabetes. Phase II clinical trials demonstrated that sitagliptin in the short-term significantly improved glycaemic control in patients with type 2 diabetes compared to placebo (two studies) and with metformin (one study). Several phase III studies are currently underway.
Authors' methods:
Overview
Details
Project Status:
Completed
Year Published:
2005
URL for published report:
http://www.hsric.nihr.ac.uk/search
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Hypoglycemic Agents
- Diabetes Mellitus, Type 2
- Sitagliptin Phosphate
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
National Horizon Scanning Centre (NHSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.